Solazyme’s Algenist Brand Wins Coveted 2014 Marie Claire Excellence in Beauty Award
SOUTH SAN FRANCISCO, Calif.—January 21, 2014—Solazyme, Inc.(NASDAQ: SZYM), a renewable oil and bioproducts company, and maker of the skincare brand, Algenist®, today announced that the line has won the prestigious 2014 Marie Claire Prix d’ Excellence de la Beauté in France. The award, which was presented at the Les Prix d’Excellence de la Beauté Marie Claire 2014 annualevent,honors exceptional advancements in innovation, efficacy, texture, design, and communication of cosmetic brands. A robust panel of French and international beauty journalists, presided by Ariane Goldet, the renowned Health and Beauty Editor of Marie Claire France, judged the competition, which included hundreds of product and brand entries. Algenist is one of only two US brands to win a prize at the 2014 awards, and was unanimously selected by the judging panel.
“Algenist delivers cutting-edge, scientific innovation based on the incredible regenerative powers of microalgae, providing visible results that demonstrate significant anti-aging properties,” said Frederic Stoeckel, SVP & General Manager, Solazyme Health Sciences, in accepting the award. “Algenist is proud to be delivering un-matched product efficacy to consumers and we are honored to be recognized for these advancements by this esteemed panel of judges and Marie Claire.”
“Algenist is one of today’s leading skincare brands that encompasses discovery, innovation, and importantly, results,” said Ariane Goldet, Health and Beauty Editor, Marie Claire. “For the past 28 years, we have searched for trailblazing products and brands that couple the latest breakthroughs with the latest trends, and Algenist with their breakthrough, hero-ingredients, Alguronic Acid® and Microalgae Oil, do all of this and more. They are a pioneering brand and we are pleased to place them amongst the 2014 Maria Claire Prix d’ Excellence de la Beauté winners.”
Harnessing the genius of microalgae and based on two potent ingredients including patented Alguronic Acidand Microalgae Oil, Algenist is a skincare brand rooted in biotechnology expertise. The award-winning line can be viewed in the February 2014 edition of Marie Claire France.
Algenist is an award-winning skincare brand harnessing the remarkable regenerative properties of microalgae and rooted in breakthrough biotechnology innovation. After a dedicated team of scientists originally tasked with researching renewable energy solutions discovered Alguronic Acid®(patented), a powerful regenerative compound produced by microalgae that functions to protect and regenerate the single-celled organism in harsh environmental conditions, it has since become a principal ingredient in many of Algenist’s prestige products. The line has since expanded to tap many of the additional benefits brought forth by this remarkable organism and today, the brand remains dedicated to using groundbreaking science to formulate revolutionary skincare innovations poised for any skin type at any age. Committed to proven results, Alguronic Acid and Microalgae Oil have undergone 3rd party clinical testing for scientifically-based efficacy claims. All Algenist products are consumer and dermatologist-tested, non-comedogenic, and hypoallergenic.
Solazyme, Inc. (SZYM) is a renewable oil and bioproducts company that transforms a range of low-cost plant-based sugars into high-value oils and food ingredients. Headquartered in South San Francisco, Solazyme’s renewable products can replace or enhance oils derived from the world’s three existing sources — petroleum, plants and animal fats. Initially, Solazyme is focused on commercializing its products into three target markets: (1) chemicals and fuels, (2) nutrition and (3) skin and personal care.
Solazyme®, Algenist®, Alguronic Acid® and the Solazyme logo are registered trademarks of Solazyme, Inc.
This press release contains certain forward-looking statements about Algenist and Solazyme, including statements that involve risks and uncertainties concerning: the attributes of the product; and the results achieved from product use. When used in this press release, the words “will”, “expects”, “intends” and other similar expressions and any other statements that are not historical facts are intended to identify those assertions as forward-looking statements. Any such statement may be influenced by a variety of factors, many of which are beyond the control of Solazyme, that could cause actual outcomes and results to be materially different from those projected, described, expressed or implied in this press release due to a number of risks and uncertainties. Potential risks and uncertainties include, among others: Algenist and Solazyme’s limited history in commercializing products; implementation risk in deploying new technologies and market acceptance of its products. Accordingly, no assurances can be given that any of the events anticipated by the forward-looking statements will transpire or occur, or if any of them do so, what impact they will have on the results of operations or financial condition of Solazyme.
In addition, please refer to the documents that Solazyme, Inc. files with the Securities and Exchange Commission, including its Quarterly Reports on Form 10-Q, as updated from time to time, for a discussion of these and other risks. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date of this press release. Solazyme is not under any duty to update any of the information in this press release.